Gilead Sciences (GILD) April weeky calls active on open
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Gilead Sciences (GILD) Remdesivir China Results 'Very Sobering' - Baird
April 23, 2020 1:34 PM EDTBaird analyst Brian Skorney weighed in on Gilead Sciences (NASDAQ: GILD) related to news that a China trial of severe patients showed remdesivir didn't improve patients' condition.
Skorney commented, "This afternoon, an abstract leaked indicating that Gilead's remdesivir failed to provide a benefit... More
